Leukemia, Myelomonocytic, Juvenile
"Leukemia, Myelomonocytic, Juvenile" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A leukemia affecting young children characterized by SPLENOMEGALY, enlarged lymph nodes, rashes, and hemorrhages. Traditionally classed as a myeloproliferative disease, it is now considered a mixed myeloproliferative-mylelodysplastic disorder.
| Descriptor ID |
D054429
|
| MeSH Number(s) |
C04.557.337.539.525 C15.378.190.615.520
|
| Concept/Terms |
Leukemia, Myelomonocytic, Juvenile- Leukemia, Myelomonocytic, Juvenile
- Leukemia, Juvenile Myelomonocytic
- Juvenile Chronic Myelogenous Leukemia
- Juvenile Myelomonocytic Leukemia
- Juvenile Myelomonocytic Leukemias
- Myelomonocytic Leukemia, Juvenile
- Myelomonocytic Leukemias, Juvenile
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myelomonocytic, Juvenile".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myelomonocytic, Juvenile".
This graph shows the total number of publications written about "Leukemia, Myelomonocytic, Juvenile" by people in this website by year, and whether "Leukemia, Myelomonocytic, Juvenile" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 3 | 1 | 4 |
| 2018 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Leukemia, Myelomonocytic, Juvenile" by people in Profiles.
-
SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation. Transfus Apher Sci. 2021 Feb; 60(1):102983.
-
Role of lncRNA Morrbid in PTPN11(Shp2)E76K-driven juvenile myelomonocytic leukemia. Blood Adv. 2020 07 28; 4(14):3246-3251.
-
Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients. Hum Mutat. 2018 04; 39(4):579-587.
-
Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia. Expert Rev Hematol. 2018 02; 11(2):129-143.
-
RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. Nat Commun. 2017 12 19; 8(1):2126.
-
Image Gallery: Juvenile cutaneous chronic graft-versus-host disease presenting as bullous pemphigoid. Br J Dermatol. 2017 09; 177(3):e69.
-
Whole Genome MBD-seq reveals different CpG methylation patterns in Azacytidine-treated Juvenile Myelomonocytic Leukaemia (JMML) patients. Br J Haematol. 2018 09; 182(6):909-912.
-
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. Br J Cancer. 2017 01; 116(3):335-343.
-
Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group. Oncotarget. 2016 May 17; 7(20):28914-9.
-
Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group. Blood. 2015 Apr 02; 125(14):2311-3.